Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
$ I5 N: J1 C# K- c1 \% L
1 c8 J2 u* M7 K; t
# h, D1 A1 B7 W6 N$ q2 |2 o6 q5 ISub-category:
6 k! J6 j+ p5 h; cMolecular Targets 2 v0 P# b3 a( t8 @" L6 T
6 d& x9 b. V5 w
4 a1 \) q' R9 H& @+ b$ \
Category:
, h( @& _+ \' D, Z, V' m+ R* T: ?Tumor Biology , D" z1 w0 X D* B; @6 ]
1 q2 c- u$ S S, V1 ] E( s7 \' E1 u- k9 M7 i0 J4 y, ~: s
Meeting:
7 |: ^- O! T7 m2011 ASCO Annual Meeting
) O. e1 [/ v7 j/ b
# d4 I% Z5 s5 d1 w! F0 ^5 k$ W, u: U/ K2 n; a ~: H% a& G: l
Session Type and Session Title:
4 A0 b0 ^; u4 }0 Q- z: v9 ePoster Discussion Session, Tumor Biology 3 H) e3 C+ O: c
! ~4 o$ O9 g2 e7 O: H# ]5 n, A) `
6 l7 g3 n) |% _ @6 c+ jAbstract No:
2 |9 W4 E$ V* {- W10517 - f% t d6 c) L: P' u
3 }# e+ v6 u' t! `
9 R( ]. ^5 E/ Q3 d% T
Citation:
3 n) E# l8 Q- _8 a( U( lJ Clin Oncol 29: 2011 (suppl; abstr 10517)
% j3 G3 J( W; I% o' M/ Z% V; e+ l7 W( w9 J6 N# D
' X6 O2 A% o1 I5 Z( k. b
Author(s):
0 o& g b7 o# J- l" J$ S# |' CJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ( a) t5 B9 }. D3 b: `. F
# j% S0 `! m7 P% d3 e! t
% ]$ y: U/ ~- H# A( r$ M7 a) z6 a( w7 w9 W$ i, |( |
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.* n; W }% j5 s! X! c2 w
9 h/ P9 X h3 h( @
Abstract Disclosures
$ Y# N5 e6 d, ^2 \7 Q' ^, B
6 o1 i" U y0 FAbstract:
. e% |7 p1 H. d! N. o6 x2 ^! `1 n% r, u+ J6 _7 A
1 {+ z0 Q* U! eBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
# J [. D" \; l, W
! ~- k2 m) x3 `5 Z8 q
/ E! \' M. M5 c, Z6 m7 \ |
0 a% Z4 @* N+ X+ ?* ~# f: `
显身卡
